Pages that link to "Q33831940"
Jump to navigation
Jump to search
The following pages link to Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells (Q33831940):
Displayed 50 items.
- Focus on adoptive T cell transfer trials in melanoma (Q21328679) (← links)
- Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells (Q24530100) (← links)
- Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells (Q24540135) (← links)
- Adoptive immunotherapy for cancer: building on success (Q24546258) (← links)
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy (Q24596055) (← links)
- T cell receptor gene therapy for cancer (Q24634774) (← links)
- Genetic engineering of T cells for adoptive immunotherapy (Q24642718) (← links)
- Adoptive cell transfer: a clinical path to effective cancer immunotherapy (Q24644774) (← links)
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells (Q24651232) (← links)
- Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response (Q26744527) (← links)
- Improving the clinical impact of biomaterials in cancer immunotherapy (Q26766267) (← links)
- Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression (Q26767514) (← links)
- Metabolic regulation of T cell differentiation and function (Q26798088) (← links)
- Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? (Q27002575) (← links)
- Current translational and clinical practices in hematopoietic cell and gene therapy (Q27024456) (← links)
- Genetically modified T cells in cancer therapy: opportunities and challenges (Q27026627) (← links)
- Lineage relationship of effector and memory T cells (Q27026665) (← links)
- Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing (Q27334215) (← links)
- Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic (Q28075992) (← links)
- T-cell receptor gene therapy--ready to go viral? (Q28081611) (← links)
- Harnessing the Microbiome to Enhance Cancer Immunotherapy (Q28088598) (← links)
- A human memory T cell subset with stem cell-like properties (Q28248395) (← links)
- Adoptive immunotherapy for cancer: harnessing the T cell response (Q28262548) (← links)
- Adoptive transfer of Mammaglobin-A epitope specific CD8 T cells combined with a single low dose of total body irradiation eradicates breast tumors (Q28386603) (← links)
- Stimulation of Wnt/ß-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype (Q28481655) (← links)
- Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors (Q28652288) (← links)
- How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer (Q28727481) (← links)
- BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models (Q28828457) (← links)
- In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. (Q30479855) (← links)
- Toward improved immunocompetence of adoptively transferred CD8+ T cells (Q33216328) (← links)
- Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion (Q33261122) (← links)
- Rapid maturation of effector T cells in tumors, but not lymphoid organs, during tumor regression (Q33296983) (← links)
- Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer. (Q33413155) (← links)
- CD4+ T cell-derived IL-2 signals during early priming advances primary CD8+ T cell responses (Q33515660) (← links)
- T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies (Q33530527) (← links)
- Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice (Q33560416) (← links)
- A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells (Q33573323) (← links)
- β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. (Q33578997) (← links)
- Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice (Q33603041) (← links)
- Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders (Q33650689) (← links)
- IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo (Q33660150) (← links)
- Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2 (Q33680751) (← links)
- Hyperthermia as an immunotherapy strategy for cancer (Q33686985) (← links)
- Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. (Q33730129) (← links)
- Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (Q33730171) (← links)
- Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma (Q33738279) (← links)
- Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. (Q33784707) (← links)
- Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes (Q33791998) (← links)
- In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies. (Q33796950) (← links)
- Limited transplantation of antigen-expressing hematopoietic stem cells induces long-lasting cytotoxic T cell responses (Q33838390) (← links)